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To	investigate	human	babesiosis	in	the	Bolivian	Chaco,	in	
2013	we	 tested	blood	samples	 from	271	healthy	persons	
living	in	2	rural	communities	in	this	region.	Microscopy	and	
PCR	indicated	that	3.3%	of	persons	were	positive	 for	Ba-
besia microti	 parasites	 (US	 lineage);	 seroprevalence	was	
45.7%.	Appropriate	 screening	 should	mitigate	 the	 risk	 for	
transfusion-associated	babesiosis.
Babesiosis is an emerging tickborne disease worldwide resulting from ≈100 Babesia parasite species that can 
infect a broad range of hosts in which it induces malaria-
like disorders. Like trypanosomes and Plasmodium spp., 
Babesia spp. can be transmitted through vertical routes and 
blood transfusions (1). Babesiosis has the greatest effect 
on the cattle industry and on companion animals; how-
ever, occasional human babesiosis has attracted increased 
attention. In immunocompetent persons, the infection is 
rarely detected because it can be asymptomatic or cause 
mild, self-resolving symptoms. However, babesiosis can 
be life-threatening in certain populations, such as neonates/
infants, elderly persons, asplenic patients, and otherwise 
immunocompromised persons (2).
The predominant species that causes of human babesio-
sis in the United States and is a rare cause of disease in Eu-
rope and Asia is Babesia microti (3), a complex that includes 
at least 4 named types and an unknown number of other 
strains (4). The second-most important zoonotic species, B. 
divergens, causes several clinical cases in Europe (5). Other 
species, such as B. duncani, B. venatorum, and some B. di-
vergens–like parasites, can cause further human infections 
worldwide (6). Many ixodid tick species can transmit Babe-
sia parasites to their natural hosts; Ixodes scapularis and I. 
ricinus are the most important human-biting vector ticks in 
the United States and Europe, respectively (7).
Three cases of uncharacterized babesiosis have been 
reported from South America, 2 from Brazil and 1 from 
Colombia (8,9). In Bolivia, only cattle have been investi-
gated, highlighting the prevalence of the species B. bovis 
and B. bigemina, unstable and endemic in the east of the 
country (10); no data are available on B. microti. Our ob-
jective was to investigate human babesiosis in the Bolivian 
Chaco, a rural region in southeastern Bolivia.
The Study
In 2013, a total of 271 healthy volunteers, residents of 2 
rural communities in southeastern Bolivia, Bartolo (Her-
nando Siles Province, Department of Chuquisaca) and 
Ivamirapinta (Cordillera Province, Department of Santa 
Cruz), completed a questionnaire interview asking for an-
amnestic data (sex, age, fever attacks, history of tick bite or 
transfusion) and provided blood samples for testing. The 
participants represented ≈50% and ≈25% of the population 
of the 2 communities, respectively. The Bolivian Ministry 
of Health and the Regional Health Departments approved 
the study design, including its ethical aspects; the Guaraní 
political organization (Asamblea del Pueblo Guaraní) sup-
ported the field work and conducted the interviews.
Blood drawn was immediately used to prepare thick 
and thin smears and to impregnate filter papers (100 
mL); serum was obtained from each remaining sample. 
Smears were Giemsa stained and examined by micros-
copy at 400× and 1,000×. DNA was extracted from all 
the dried blood spots by using Dried Blood Spot DNA 
Isolation Kit (Norgen Biotek Corp., Thorold, ON, Can-
ada) and amplified by PCR with generic apicomplexan 
18S rRNA-specific primers (11). Amplicons (≈1,700 bp) 
were purified (Sure Clean kit; Bioline, Rome, Italy) and 
then sequenced. Sequences were aligned and compared 
with those available in GenBank. To investigate the B. 
microti strain, we further examined all positive samples 
by lineage-specific PCR based on the subunit 7 (η) of the 
chaperonin-containing t-complex polypeptide 1 (CCTη) 
gene, following the published protocol (4). PCR-positive 
samples and further randomly chosen serum samples (n = 
47 for each community) were checked by an indirect fluo-
rescent antibody test (IFAT) (IgG IFA kit; Fuller Labo-
ratories, Fullerton, CA, USA) for reactivity to B. microti, 
following the manufacturer’s instructions and fixing the 
cutoff value at dilution 1:64. Positive and negative control 
sera supplied by the kit were included on each IFAT slide. 
IFAT sensitivity and specificity in detecting B. microti an-
tibodies, reported by the kit data sheet, are 88%–96% and 
90%–100%, respectively (12). To ensure the specificity 
of the results, we further tested all reactive serum samples 
and 10 negative serum samples with the Falciparum-Spot 
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IF kit (bioMérieux, Marcy l’Etoile, France) to detect plas-
modial antibodies.
We conducted statistical analyses using the χ2 test. We 
considered p<0.05 as significant.
Of the 271 serum samples, 9 (3.3%; 95% CI 0.97%–
5.03%) thin and thick smears, from 5 (4.1%) and 4 (2.7%) 
participants living in Bartolo and Ivamirapinta, respective-
ly, were positive for B. microti (Table; Figure). Infection 
rates did not differ significantly by community (p = 0.55), 
sex, or age, despite early infection in Bartolo.
Testing of blood from the 9 positive participants by 
molecular amplification and sequencing confirmed mor-
phologic diagnosis (99% nt identity with the B. microti 
18S rRNA gene; GenBank accession no. AY693840.1); 
moreover, results classified all the remaining blood spots 
as negative. PCR on the CCTη gene and sequencing 
showed that all positive samples belonged to the US lin-
eage Gray strain (100% nt identity with GenBank acces-
sion no. AB362586.1). Sequences obtained were deposited 
in GenBank under accession nos. KT318131, KT318132, 
and KT844553–KT844568.
IFAT showed reactivity to B. microti antigens in all 
positive survey participants and in 34 of 85 additional per-
sons, providing an overall seroprevalence of 45.7% (95% 
CI 35.7%–55.7%). We observed no differences between 
the 2 communities (p = 0.836) by age group or between 
early (0–30-year-olds) or late (>30-year-olds) developed 
seroreactivity (Bartolo: p = 0.209; Ivamirapinta: p = 0.760). 
We found no cross-reactivity to plasmodial antigens.
Conclusions
Although our study has some limitations, including the 
cross-sectional design, the limited number of human sam-
ples, and the nonrandom sampling, we detected B. microti 
antigens in ≈3% of persons living in the rural communities 
of the Bolivian Chaco. Moreover, we detected an overall 
seroprevalence rate of ≈45%, higher than that reported in 
Colombia (30.6%) (13), and with exposure starting from 
an early age. None of the positive study participants had 
signs or symptoms of babesiosis at the time of sample col-
lection. Considering that many intra-erythrocytic cycles are 
needed before the immune system responds to the parasite 
and starts antibody production (14), the contemporary de-
tection in some cases of blood parasite and serum-specific 
antibodies suggests a late infection stage.
The presence of B. microti antigens in persons with-
out a history of tick infestation or transfusions indicates 
that contact between ticks and humans is not rare (mainly 
in young persons), as confirmed by a serosurvey that evi-
denced human exposure to other tickborne pathogens, such 
as Borrelia spp. (15). Furthermore, this finding suggests 
that, even though the primary reservoir, the white-footed 
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Table.	Babesia microti results	from	microscopy,	PCR,	and	serology	in	persons	living	in	2	rural	communities,	southeastern	Bolivia,	
2013* 
Age	group,	y 
No.	positive/no.	examined	(%) 
Bartolo 
 
Ivamirapinta 
Microscopy	and	PCR IFAT Microscopy	and	PCR IFAT 
1–10 2/29	(6.9) 3/9	(33.3)  1/21(4.7) 5/6	(83.3) 
11–20 1/16	(6.2) 1/3	(33.3)  0/42	(0) 3/10	(30) 
21–30 1/23	(4.3) 7/7	(100)  1/15	(6.6) 1/3	(33.3) 
31–40 0/19	(0) 3/4	(75)  1/21	(4.7) 2/3	(66.6) 
41–50 0/11	(0) 0/2	(0)  0/13	(0) 3/4	(75) 
51–60 1/11	(9.0) 2/8	(25)  0/13	(0) 2/6	(33) 
61–70 0/10	(0) 5/10	(50.0)  1/15	(6.6) 4/11	(36.4) 
>70 0/4	(0) 1/4	(25)  0/8	(0) 1/4	(25) 
Total 5/123	(4.1) 22/47	(46.8)  4/148	(2.7) 21/47	(44.7) 
*IFAT,	indirect	fluorescent	antibody	test. 
 
Figure. Babesia microti 
parasites	(arrows)	detected	
in	Giemsa-stained	thin	(A)	
and	thick	(B)	blood	smears	
from	persons	living	in	2	rural	
communities,	southeastern	
Bolivia,	2013.	Scale	bars	 
	indicate	10	μm.
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mouse (Peromyscus leucopus), has been reported only in 
North and Central America, natural animal hosts of this 
protozoon are widespread in the studied area. Inhabitants 
of both communities live in close contact with domestic 
animals, such as dogs, chickens, and pigs, and with deer 
and other wild animals, which might contribute to the 
maintenance and spread of the ticks. Because this zoonotic 
babesiosis is due to the Gray strain, previously documented 
in humans in the United States, Germany, Russia, China, 
South Korea, and Japan, where it is harbored by various 
small mammals, further studies are needed to explore its 
vectors and reservoirs in the rural areas here investigated.
Human babesiosis is probably an underestimated 
health problem in the Bolivian Chaco. Residents should 
therefore be alerted to the threat posed by ticks, and physi-
cians should be aware of infection with B. microti parasites 
as a potential life-threatening disease. The presence of B. 
microti antigens in the blood of asymptomatic persons is 
of concern in terms of the possible risk for transfusion-as-
sociated babesiosis and should prompt the need to evaluate 
implementation of appropriate screening measures.
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